J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas.
Julie M. Vose,Cary Peterson,Philip J. Bierman,Dennis D. Weisenburger,James Linder,Douglas S. Harrington,William P. Vaughan,Anne Kessinger,James O. Armitage +8 more
TL;DR: Analysis of the response to autologous transplantation in these two patient populations revealed a slightly better complete response rate for patients with T-cell lymphoma, and equivalent long-term survival and disease-free survival in both relapsed T- and B-cell non-Hodgkin's lymphoma.
Journal ArticleDOI
ATM, CTLA4, MNDA, and HEM1 in High versus Low CD38–Expressing B-Cell Chronic Lymphocytic Leukemia
Avadhut D. Joshi,Ganapati V. Hegde,John D. Dickinson,Amit K. Mittal,James C. Lynch,James D. Eudy,James O. Armitage,Philip J. Bierman,R. Gregory Bociek,Marcel P. Devetten,Julie M. Vose,Shantaram S. Joshi +11 more
TL;DR: Down-regulation of HEM1 expression in patient CLL cells resulted in a significant increase in their susceptibility to fludarabine-mediated killing and ATM expression was found to be significantly lower in CD38 high compared with CD38 low CLL as confirmed by real-time reverse transcription-PCR.
Journal ArticleDOI
Diffuse Large B-cell Lymphoma Arising in Nodular Lymphocyte Predominant Hodgkin Lymphoma. A Report of 21 Cases from the Nebraska Lymphoma Study Group
James Z. Huang,Dennis D. Weisenburger,Julie M. Vose,Timothy C. Greiner,Patricia Aoun,Wing C. Chan,James C. Lynch,Philip J. Bierman,James O. Armitage +8 more
TL;DR: It is suggested that patients with DLBCL arising in NLPHL have a prognosis similar to those with de novoDLBCL and should be treated aggressively.
Journal ArticleDOI
A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
Andrew M. Evens,Sriram Balasubramanian,Julie M. Vose,Wael A. Harb,Leo I. Gordon,Robert M. Langdon,Julian Sprague,Mint Sirisawad,Chitra Mani,Jeanne Yue,Ying Luan,Sharon Horton,Thorsten Graef,Nancy L. Bartlett +13 more
TL;DR: The pan-HDACi, abexinostat, was overall well tolerated and had significant clinical activity in follicular lymphoma, including highly durable responses in this multiply relapsed patient population.
Journal ArticleDOI
Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience.
Apar Kishor Ganti,Dennis D. Weisenburger,Lynette M. Smith,Christine P. Hans,Robert G. Bociek,P. J. Bierman,Julie M. Vose,James O. Armitage +7 more
TL;DR: Less than half of the patients with FL3 and a diffuse component of < or =50% treated with anthracycline-based combination chemotherapy will relapse and relapses are uncommon after 6 years, suggesting older patients should be offered the same aggressive chemotherapy as younger patients.